Diabetes Care Drugs and Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The diabetes care drugs and devices market size was at USD 120.35 billion in 2025 and stands at USD 130.71 billion in 2026. This report is Segmented by Drug Type (Insulin, GLP-1 Receptor Agonists, and More), Device Type (Monitoring Devices, Management Devices), Patient Type (Type 1, and More), End User (Hospitals and Clinics, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Diabetes Care Drugs and Devices Market Trends and Insights

Rapid Reimbursement Expansion for Continuous Glucose Monitoring

The diabetes care drugs and devices market is gaining from policy changes that are turning interest in continuous monitoring into actual use in daily care. In the United States, Medicare expanded access effective January 2025 by removing the earlier requirement for repeated daily fingerstick testing, which opened eligibility to a wider group of insulin users and people with documented problematic hypoglycemia.That matters because reimbursement often decides whether a patient tries sensor-based monitoring at all, especially in older populations where recurring device cost can delay adoption. Better access to CGM in 2025 and 2026 also improves treatment follow-through because patients can see glucose response more clearly and respond faster to therapy changes at home. In the diabetes care drugs and devices market, this creates a link between device reimbursement and broader therapy use, since monitoring tools can support stronger persistence with injectable and insulin-based regimens. This is why reimbursement policy now shapes not only device demand, but also the pace of treatment intensification across the wider care pathway in the diabetes care drugs and devices market.

Rising Global Diabetes Prevalence and Treatment Intensification

The diabetes care drugs and devices market continues to expand because the underlying patient base remains very large and still has significant unmet treatment need. The International Diabetes Federation reported in 2025 that 43% of adults living with diabetes in 2024 remained undiagnosed, which means the current treatment pool still understates long-term demand. The report also noted in 2025 that nearly 90% of the undiagnosed population lived in low- and middle-income countries, which points to future demand growth across both basic therapies and advanced monitoring as diagnosis rates improve. At the same time, diagnosed patients are moving toward more intensive treatment plans that combine newer drug classes with data-driven monitoring, raising revenue per patient rather than only increasing patient numbers. In February 2026, Novo Nordisk reported its fiscal 2025 results, confirming that GLP-1-based diabetes sales continued to contribute meaningfully even as obesity products grew faster. That combination of wider diagnosis and deeper treatment use is giving the diabetes care drugs and devices market a stronger growth base across both its drug and device segments.

High Out-of-Pocket Cost for Advanced Devices and Branded Therapeutics

The diabetes care drugs and devices market still faces a clear affordability problem in advanced product categories. In 2025, FDA-approved CGM systems were described in the source material as costing USD 100 to USD 400 per month before insurance, and that still left meaningful patient exposure even where coverage existed. In lower-income and price-sensitive markets during 2025 and 2026, that challenge became more severe and kept many patients on older monitoring formats instead of shifting them into continuous sensing or premium drug therapy. High cost can also reshape channel behavior, because patients who cannot afford standard branded access may search for lower-cost supply routes that are less consistent and harder to supervise. In the diabetes care drugs and devices market, this slows adoption beyond well-insured groups and limits how fast innovation can scale into broad routine use. It also means that strong clinical value alone is not enough if the patient still cannot maintain access month after month.

Other drivers and restraints analyzed in the detailed report include:

• Faster Adoption of Connected Insulin Delivery and Smart Monitoring
• EU MDR and Other Re-certification Bottlenecks for Legacy Devices

Segment Analysis

Insulin held 38.8% of the drug segment by value in 2025, which kept it in the leading position across treatment categories in the diabetes care drugs and devices market. That position reflects its essential role in type 1 care and its continued importance in large parts of type 2 management, especially in markets where cost still shapes prescribing choices. Even so, growth momentum is moving toward drug classes that offer a wider clinical value proposition and stronger commercial expansion potential. In 2026, clinical guidance and commercial activity both continued to support newer treatment classes with broader cardiometabolic relevance. The shift does not reduce insulin’s relevance, but it does change where future mix improvement is likely to come from in the diabetes care drugs and devices market.

GLP-1 receptor agonists are forecasted to grow at a 16.5% CAGR from 2026 to 2031, making them the fastest-growing drug class in the diabetes care drugs and devices market. Their expansion is being supported by broader use in cardiometabolic care and by stronger physician confidence in long-term outcomes beyond glucose control alone. In January 2026, IRA-negotiated Medicare prices took effect for selected drugs, which added another pricing and access variable for branded diabetes therapies. SGLT2 inhibitors are also gaining importance in 2026 because guidelines are bringing diabetes therapy closer to heart failure and kidney disease management in routine practice. Oral GLP-1 formats remain strategically important through the forecasted period because they can help expand access among patients who still hesitate to begin injectable therapy.

Monitoring devices held 65.4% of device segment revenue in 2025, giving them the largest diabetes care drugs and devices market share within the device category. This lead reflects how quickly continuous monitoring moved into the mainstream for insulin users and how steadily it spread into broader type 2 care. The category is being led by sensor ecosystems that make daily tracking easier, extend wear time, and fit more naturally into patient routines. In April 2025, Dexcom received FDA clearance for its G7 15-Day CGM, which showed continued movement toward longer wear formats. It also explains why the device mix in the diabetes care drugs and devices market is staying weighted toward monitoring even as management systems improve.

Management devices are projected to grow at a 10.7% CAGR through 2031, which makes them the fastest-expanding device segment in the diabetes care drugs and devices market. In January 2026, Medtronic received FDA clearance for the MiniMed Go Smart MDI system, and in June 2026, MiniMed expanded its Abbott partnership around dual glucose-ketone sensors. In May 2026, Abbott also secured CE Mark for Libre Duo, which reinforced the move toward more clinically advanced sensing within insulin management. These steps show that growth in management devices is increasingly tied to connected design rather than stand-alone delivery hardware. In practical terms, the companies that can combine sensor data, decision support, and dosing tools most effectively are likely to hold the strongest long-term position in this part of the diabetes care drugs and devices market.

Complete Report Scope:

• By Drug Type
  • Insulin
  • GLP-1 Receptor Agonists
  • SGLT2 Inhibitors
  • DPP-4 Inhibitors
  • Other Diabetes Drugs
• By Device Type
  • Monitoring Devices
    • Self-Monitoring Blood Glucose Devices
      • Glucometer Devices
      • Test Strips
      • Lancets
    • Continuous Glucose Monitoring Devices
      • Sensors
      • Durables
  • Management Devices
    • Insulin Pumps
      • Insulin Pump Device
      • Insulin Pump Reservoir
      • Infusion Set
    • Insulin Delivery Consumables
      • Insulin Syringes
      • Insulin Pens
      • Jet Injectors
• By Patient Type
  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational and Other Diabetes Types
• By End User
  • Hospitals and Clinics
  • Home Care Settings
  • Ambulatory Surgical Centres
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce and Direct-to-Consumer Channels
  • Diabetes Specialty Clinics and Institutional Supply
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • Middle East
      • GCC
      • South Africa
      • Rest of Middle East and Africa

Geography Analysis

North America held 39.6% of global revenue in 2025, which gave it the largest regional position in the diabetes care drugs and devices market share. The region’s lead reflects high per-patient treatment spending, broad insurance infrastructure, and early use of premium CGM and automated insulin delivery systems. In the United States, Medicare coverage changes effective from January 2025 further improved access to CGM for insulin-using patients and people with problematic hypoglycemia. Canada adds a steadier base through provincial reimbursement, while Mexico remains more underpenetrated and more concentrated in private care settings. Even in this large regional block, prior authorization and affordability in 2025 and 2026 still shape how quickly advanced solutions spread across everyday use.

Asia-Pacific is forecasted to grow at a 10.7% CAGR from 2026 to 2031, making it the fastest-growing regional component of the diabetes care drugs and devices market. The region combines a large diabetes burden with improving access to diagnosis, basic therapy, and device reimbursement in several major markets. In Q3 2025, tirzepatide posted 251% year-on-year sales growth in Japan, which signaled strong premium therapy adoption in a mature market. In February 2026, Abbott India and Novo Nordisk entered a co-promotion agreement in India, showing how affordability-focused partnerships are being used to widen access in high-volume markets. Together, these developments make Asia-Pacific the main long-term expansion zone for the diabetes care drugs and devices market.

Europe remains a substantial part of the diabetes care drugs and devices market, supported by established reimbursement structures and specialist care networks in major countries. In 2025, MedTech Europe continued to highlight the operational strain tied to MDR recertification, and that pressure is carrying directly into the 2026 to 2027 renewal cycle. In July 2026, Diabeloop’s DBLG2 closed-loop system received CE Mark for initial launch in Germany, which showed that innovation in automated delivery was still moving forward despite the regulatory burden. South America remains more sensitive to affordability, while the Middle East and Africa show a split between stronger premium uptake in wealthier Gulf countries and slower progress in lower-income settings with procurement and logistics limits. This leaves the wider regional picture uneven, but still relevant for long-term expansion beyond the largest established markets.

List of Companies Covered in this Report:

• Abbott Laboratories
• A. Menarini Diagnostics srl
• Arkray
• Ascensia Diabetes Care Holdings AG (PHC Holdings Corporation)
• AstraZeneca
• Bayer
• Beckton Dickinson
• Bionime
• Dexcom
• Eli Lilly and Company
• Embecta Corp.
• Roche
• Insulet
• LifeScan Enterprises LLC
• Medtronic
• Nipro
• Novo Nordisk
• Sanofi
• Senseonics
• Tandem Diabetes Care
• Terumo
• Trividia Health, Inc.
• Ypsomed

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support